MaxCyte, Inc. announced that Ron Holtz, who served as MaxCyte's CFO from 2005 until September 2020 and again since May 2022, having served as Chief Accounting Officer during the interim period, will take on the role of EVP, Administration for the Company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
370 GBX | -.--% | +1.37% | +4.96% |
22/05 | MaxCyte inks deal with Legend Biotech for tech supply | AN |
22/05 | MaxCyte Signs License Deal With Legend Biotech for Cell Therapy Program | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.96% | 49Cr | |
+7.01% | 22TCr | |
+11.01% | 19TCr | |
+19.20% | 14TCr | |
+30.79% | 11TCr | |
+1.48% | 6.46TCr | |
+13.95% | 5.24TCr | |
-0.16% | 4.85TCr | |
-6.20% | 3.8TCr | |
+0.91% | 3.56TCr |
- Stock Market
- Equities
- MXCT Stock
- News MaxCyte, Inc.
- MaxCyte, Inc. Appoints Ron Holtz as EVP, Administration